Milrinone Inhaled in Cardiac Surgery

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Pulmonary hypertension is an important morbidity factor in patients having to undergo cardiac surgery with cardiopulmonary bypass (ECC). Milrinone used in inhalation, shows evidence of being a pulmonary vasodilator able to possibly contribute to the reduction of pressure on the pulmonary artery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Andre Denault
• Collaborators: Canadian Anesthesiologists' Society; Heart and stoke fondation of Quebec; Organon
• Treatments: Milrinone

Criteria

Inclusion Criteria:

• Adult patients scheduled for elective valvular or complex (2 or more valves or

• valve and revascularization) cardiac surgery under CPB with preoperative PHT defined as mean pulmonary artery pressure (MPAP) over 30 mmHg or

• systolic pulmonary artery pressure (SPAP) over 40 mmHg (using preoperative right-sided catheterization or estimated by echocardiography).

Exclusion Criteria:

• Cardiac surgery not requiring CPB, contraindication to TEE (esophageal pathology or unstable cervical spine) and emergency surgery.

• Patients will be recruited the day before surgery and randomized using computerized cards by the pharmacy department